Eusol Biotech Company Description

Eusol Biotech Co.,Ltd. focuses on research and development of new drugs for the treatment of nerve injuries in Hong Kong and Taiwan.

The company’s pipeline includes ES135, a recombinant human acidic fibroblast growth factor (rhFGF1) for spinal cord injury that is in phase 1, 2, and 3 clinical trials, and SM-1, a 3-in-1 combination sleeping aid.

It also offers small molecule drugs including EPS221, a selective serotonin reuptake inhibitor; EPS222, a calcium channel blocker for cardiovascular disease; EPS251, a drug for rheumatology/anti-inflammation; and EA2501, a drug for anticoagulation.

The company was founded in 1994 and is headquartered in Taipei, Taiwan.

Eusol Biotech Co.,Ltd.

Country	Taiwan
Founded	1994
Industry	Biotechnology
Sector	Healthcare
CEO	Wan-Ya Zhang

Contact Details

Address: No. 367, Fuxing North Road Taipei, 105401 Taiwan
Phone	886 2 2718 5128
Website	eusol-biotech.com

Stock Details

Ticker Symbol	6652
Exchange	Taipei Exchange
Fiscal Year	January - December
Reporting Currency	TWD
ISIN Number	TW0006652001
SIC Code	2836

Key Executives

Name	Position
Wan-Ya Zhang	Manager
Bing Song Li	Accounting Supervisor